Dr David Ribeiro, CEO of ProAxsis, will be attending the Anglonordic Life Sciences Conference, taking place in London this week, and will be presenting a company update as part of the Biotech Investment Programme at 2pm on May 31st. This will be the 14th annual meeting of this partnering conference.
Dr Ribeiro said: “This is the first time that we’ll have participated in this event, so I’m very much looking forward to engaging with the attendees from the investor and biotech communities. Our point-of-care test for monitoring active neutrophil elastase in diseases such as COPD and cystic fibrosis is in its final stages of development, so this is an excellent time for us to be meeting prospective partners for this exciting technology.”
Any requests from either pharmaceutical companies or academic researchers for support to measure active proteases or other inflammatory biomarkers can be directed to info@proaxsis.com.
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.
Related News
Introduction As 2022 commences, I am pleased to provide an update on the progress made with regard …
ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes …
Introduction In parallel with the release of the company’s 2020 financial statements, I am pleased to provide …